Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, et al.
Journal for Immunotherapy of Cancer
|
April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG
Sören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
European Journal of Cancer (Oxford, England : 1990)
|
March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, et al.
Journal for Immunotherapy of Cancer
|
April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG
Sören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Page
of 4